beta-Lactamase Inhibitors
"beta-Lactamase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES.
| Descriptor ID |
D065093
|
| MeSH Number(s) |
D27.505.519.389.400 D27.505.954.122.085.516
|
| Concept/Terms |
beta-Lactamase Inhibitors- beta-Lactamase Inhibitors
- Inhibitors, beta-Lactamase
- beta Lactamase Inhibitors
- Inhibitors, beta Lactamase
- Lactamase Inhibitors, beta
- beta Lactamase Antagonists
- Antagonists, beta Lactamase
- Lactamase Antagonists, beta
|
Below are MeSH descriptors whose meaning is more general than "beta-Lactamase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "beta-Lactamase Inhibitors".
This graph shows the total number of publications written about "beta-Lactamase Inhibitors" by people in this website by year, and whether "beta-Lactamase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "beta-Lactamase Inhibitors" by people in Profiles.
-
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
-
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
-
Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183.
-
New ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1).
-
What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on ?-Lactam/?-Lactamase Inhibitor Combinations. Clin Lab Med. 2019 09; 39(3):473-485.
-
Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 02; 63(2).
-
In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7.
-
Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40.